- Home
- RNXT vs LSTA Comparison
RNXT vs LSTA Comparison
Compare RNXT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | LSTA |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 20.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | LSTA |
|---|---|---|
| Price | $0.90 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.75 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 195.2K | 22.0K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $928,000.00 | ★ $1,070,000.00 |
| Revenue This Year | $2,795.35 | N/A |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $1.81 |
| 52 Week High | $1.69 | $4.20 |
Technical Indicators
Market Signals| Indicator | RNXT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 48.94 |
| Support Level | $0.83 | $1.96 |
| Resistance Level | $1.00 | $2.10 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 44.95 | 68.13 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.